2023 will be a tough year for pre-revenue biotech firms to go public in Hong Kong, according to Serena Shao, founder and managing partner of healthcare-focused investment firm Ascendum Capital.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
